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Wehave investigated a rapidly reversible hydro-
phobization of therapeutic agents for improving
first-pass uptake in locoregional drug therapy.
This approach involves the attachment of
ahydrophobicmoiety to thedrugbyhighly labile
chemical linkages that rapidly hydrolyze upon
injection.Hydrophobizationdrastically enhances
cell-membrane association of the prodrug and,
consequently, drug uptake,while the rapid labil-
ity protects nontargeted tissues from exposure
to the highly active agent. Using the mem-
brane-impermeableDNA intercalatorpropidium
iodide, andmelphalan, we report results from in
vitro cellular internalization and toxicity studies.
Additionally, we report in vivo results after a sin-
gle liver arterial bolus injection, demonstrating
both tumor targeting and increased survival in
a mouse tumor model.
INTRODUCTION
Attempts to improve the therapeutic index of drugs for
tumor treatment have led to advancements in both pro-
drug design and drug-delivery systems [1–3]. Targeted
delivery systems comprising liposomal, polymeric conju-
gate, micelle, polymeric micelle, and nanoparticles that
employ active (receptor and antibody mediated) and pas-
sive (enhanced permeability and retention) tumor target-
ing have been described [4–13]. A particularly valuable
component for the design of these advanced systems
involves the use of hydrolytically or enzymatically labile
chemical linkages, most notably cis-aconityl and hydra-
zones, in order to release the drug from the delivery sys-
tem [7, 8, 14, 15].
Despite the advances in drug delivery, the treatment of
liver tumors has remained problematic. The liver is the site
of both primary tumors, such as hepatocellular carcinoma
(HCC) and cholangiocarcinoma, and a variety of second-
ary metastatic malignancies [16, 17]. Traditional systemic
chemotherapy has demonstrated poor antitumor benefit
and only marginal increases in survival. As a result, resec-Chemistry & Biology 14, 1065–1077tion and transplantation remain the only curative options,
but a variety of factors often eliminate these possibilities
[18–20]. These limitations have fostered the development
of locoregional drug treatment strategies, such as direct
hepatic artery infusion (HAI) and transcatheter hepatic
artery chemotherapy (TAC) [21–26]. These approaches
exploit the difference in the vascular supply of tumor and
normal parenchyma; hepatic tumors are fed by a neovas-
cularized hepatic arterial route, while the normal liver
parenchyma is supplied mainly from the portal vein [27,
28]. Based on the idea of high first-pass drug extraction,
drug delivery to the hepatic artery would result in the
delivery of higher doses of drugs to the liver tumors, while
decreasing normal hepatic tissue exposure, therefore
minimizing drug-related toxicities [29, 30]. Unfortunately,
despite the initial intrigue and several trials, the results to
date have not been encouraging, even when combined
with embolization in order to prolong drug contact with
the tissue [31]. The limited benefit observed suggests
that poor first-pass drug extraction by the tumor tissue
remains a serious issue.
This report details the development of prodrugs with
enhanced first-pass extraction, due to transient hydro-
phobic modification. Drug hydrophobization utilizing rela-
tively stabile modifications such as esters and amides was
shown to increase drug interactions with cellular mem-
branes and has correlated with improved cellular uptake
and lowered IC50 values [32–35]. However, concerns re-
main involving both compound aggregation and emboli-
zation, as well as the sequestering of the drug in the cell
membrane [36]. In order to address these issues, we
have developed a new approach, to our knowledge, to hy-
drophobization in which the drug is linked to a hydropho-
bic moiety by highly labile chemical linkages. Our results
show that this approach, termed RRH for rapidly revers-
ible hydrophobization, has great promise for selective
first-pass extraction. Because the attachment linkages
for the hydrophobic moieties are rapidly hydrolyzed,
prodrug that is not extracted during a first-pass exposure
rapidly reverts to the less membrane-permeable parent
drug, enabling selective targeting of organs and tumors.
The conceptual basis of this approach is presented in
Figure 1.
We have investigated the modification and delivery of
propidium iodide (PI), a non-membrane-permeable DNA, September 2007 ª2007 Elsevier Ltd All rights reserved 1065
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Labile Hydrophobization for First-Pass DeliveryFigure 1. A Conceptual Schematic of the
Cellular Delivery of a RRH Prodrug, a
Stable Prodrug, and a Standard Drug
In the context of first-pass extraction, the RRH
prodrug provides high levels of membrane at-
tachment and internalization, while the prodrug
that was not extracted reverts to the less mem-
brane-active drug form. The hydrophobically
modified prodrug with a stable linkage pro-
vides high levels of membrane attachment,
followed by internalization by endocytosis.
However, prodrug not extracted in a first-
pass setting is still membrane active to other
cells and tissues not being targeted. The drug
itself has little cellular uptake and is available
to other cells and tissues systemically.intercalator, as a fluorescent reporter drug, and the antitu-
mor agent melphalan. Hydrophobization of PI with very
labile hydrophobic moieties substantially increased its
entry into cells both in vitro and in vivo. Increased cellular
uptake led to dramatically lower IC50 values in vitro. Hydro-
phobization of melphalan lowered IC50 values in vitro. We
further report that a single liver arterial bolus injection of a
RRH-PI prodrug significantly increased survival in a mouse
MC38 liver tumor model.
RESULTS
The goal of RRH prodrugs is to increase the therapeutic
index of drugs for first-pass extraction by creating a
membrane-permeable compound for a very limited time.
We reasoned that hydrophobization could be utilized to
increase the drug’s affinity for membranes and thereby
increase drug-uptake levels. In essence, hydrophobicity
is utilized as a means of cell targeting. By incorporating
rapid lability into the hydrophobic system, we hoped to
both reduce the possibility of embolization after delivery
and exclude targeting of remote tissues, thereby limiting
systemic exposure. Conceptually, the prodrug should
only survive long enough to reach and treat the tissue of
interest and should revert to the parent drug prior to
encountering other remote tissues. In order to further limit
drug uptake in these nontargeted cells, an ideal drug can-
didate would exhibit good cellular uptake as the hydro-
phobic prodrug and relatively little cellular uptake in its
native form.
In order to test this idea of RRH modification on
a membrane-impermeable compound, we chose to con-
duct our initial investigation on the DNA intercalator pro-
pidium iodide (PI). PI does not traverse uncompromised
cell membranes, a property that is the basis of its wide-
spread application as an indicator of cell viability. Addi-1066 Chemistry & Biology 14, 1065–1077, September 2007 ª20tionally, PI exhibits a 20- to 30-fold enhanced fluores-
cence upon intercalation into DNA, facilitating detection
of PI-positive cells. As a DNA intercalator, PI could also
induce cytotoxicity by interfering with DNA replication
and transcription [37, 38]. Chemically, PI possesses
two amino groups at the three and eight positions of
the phenanthridinium ring system that are available for
modification (Figure 2).
Chemical Synthesis and Lability of RRH Prodrugs
Studies involving the basicity and modification of the 3,8-
amino groups of ethidium (a closely related phenanthridi-
nium) have demonstrated that the exocyclic amines are
poor nucleophiles and weak bases (pKa = 0.8 and 2),
necessitating the use of highly reactive electrophiles
[39]. In the case of PI, we expected similar reactivity,
and we therefore investigated two different approaches
for labile hydrophobization. In the first approach, attach-
ment of two octadecyl chains to PI was accomplished
by the reaction of PI and chloro(dimethyl)octadecyl-silane
(DMODSiCl) under basic conditions in either DMSO or
DMF, affording the bis-silazane II in essentially quantita-
tive yield after precipitation with diethyl ether (Figure 2).
Although silazanes are well known, this modification has
found only limited utility, in part due to rapid hydrolysis
[40]. We believed, however, that this hydrolytic instability
could be taken advantage of in our approach, if the
prodrug could survive long enough to reach tissues of
interest. Two additional compounds, a trisilylated PI and
the anilinium salt of II, were identified as minor compo-
nents in some of the reaction mixtures by 1H-NMR
(<10%). These compounds would be expected to show
similar hydrolysis properties as II, and they were therefore
not thought to be significant contaminants. Mass analysis
of II indicated the mass for PI (and fragmentation prod-
ucts), presumably due to the hydrolysis during analysis.07 Elsevier Ltd All rights reserved
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Labile Hydrophobization for First-Pass DeliveryFigure 2. Structures for PI, PI Derivatives, and Melphalan DerivativesA second modification approach utilized an amidation
reaction between PI and the disubstituted maleic anhy-
dride derivative N-dodecyl-3-(4-methyl-2,5-dioxo-2,5-
dihydro-furan-3-yl)-propionamide (C12PMMA), to form
the bis-maleamic acid III (Figure 2) as a mixture of isomers
(arising from the amidation and ring-opening reaction
occurring on either of the carbonyl groups of the cyclic
anhydride). Maleamic acids are known to be labile under
acidic pH, reverting to the amine and the cyclic anhydride;
the derivatives of disubstituted maleic anhydride shows
the most rapid rate of hydrolysis (t1/2 = 5 min at pH 5)
[41]. Recent publications have detailed the use of hy-
drophobic maleic anhydride derivatives similar to
C12PMMA for the reversible aqueous lipidation (REAL)
of peptides, resulting in improved oral bioavailability [42,
43]. Although unstable at acidic pH, it was suggested
that the REAL peptide survived the acidity encountered
in the stomach due to precipitation of the derivative at
acidic pH. In our system, however, we believed that the
decreased nucleophilicity of the PI exocyclic nitrogens
relative to aliphatic amines would result in a greatly en-
hanced rate of hydrolysis for III relative to the previously
studied derivatives.Chemistry & Biology 14, 1065–1077In order to test the effect of the rapid lability in our sys-
tem, we also constructed a stable hydrophobic derivative
of PI. Amidation of PI with lauroyl chloride was conducted,
affording IV in 96% yield (Figure 2). The use of IV as a con-
trol compound in our uptake studies was facilitated by its
fluorescent detection in the fluorescein channel. In order
to test the effect of reversible hydrophobization with
a known chemotherapeutic in a first-pass setting, we
also modified melphalan with C12PMMA to afford malea-
mic acid, V (Figure 2). Based on amine pKa (melphalan
pKas = 9.13 and 1.83; [44]), we expected that V would
hydrolyze slower than the corresponding PI derivative, III.
The prodrugs were tested for their rate of hydrolysis at
pH 6.0, 7.2, and 8.5 by using fluorescent spectroscopy
(Table 1). Hydrophobization of PI resulted in a shift in the
excitation maximum and a decrease in the measured fluo-
rescence of the RRH-PI. Upon the addition of aqueous
buffer to II or III, there was a rapid increase in fluores-
cence, indicating the loss of the hydrophobic group and
reversion of the RRH-PI to unmodified PI. The silazane II
was hydrolytically unstable, with a calculated t1/2 of 23 s
at pH 8.5. As the pH of the buffer was decreased to pH
7.2, the rate of hydrolysis increased (t1/2 = 11 s). A similar, September 2007 ª2007 Elsevier Ltd All rights reserved 1067
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Labile Hydrophobization for First-Pass DeliveryTable 1. Half-Life Values for RRH-PI and Melphalan Prodrugs
Compound
Half-Life (k)
pH 8.5 pH 7.2 pH 6.0
II 23.1 s (1.80 min1) 10.5 s (3.96 min1)
III 21.1 s (1.97 min1) 8.24 s (5.05 min1)
IV nonlabile nonlabile
V 25.7 s (1.62 min1)trend was observed for III, with t1/2s of 21 s (pH 8.5) and 8 s
(pH 7.2). Hydrolysis of V was monitored by the reaction of
the liberated melphalan with fluorescamine, resulting in
a t1/2 of 26 s at pH 6.0.
In Vitro Cellular Uptake Studies
Due to the instability of the RRH-PI prodrugs in water, it
was necessary to dissolve them in a small amount of
organic solvent (OS) and mix them with an aqueous solu-
tion immediately prior to delivery. There is precedence (for
example, Onyx Liquid Embolic System) for the use of an
OS in drug delivery. Rapid and efficient mixing was critical
in order to avoid cellular damage or toxicity from the OS.
Damaged cells would indicate successful PI uptake, inter-
fering with the analysis of drug hydrophobization. We
therefore constructed a small passive mixing chamber
with colliding flows that utilized two syringe pumps for
solution delivery (Figure 3A) [45, 46]. Testing with this
mixing chamber (PI in DMF and isotonic glucose) resulted
in very little PI uptake in cells, and results were compara-
ble to those from control experiments in which an aqueous
solution of PI (no OS) was added to the cell media. This
indicated that the chamber was effective at mixing the
solutions, resulting in no cellular PI uptake due to OS-
mediated toxicity. This mixing chamber was utilized in all
of the described experiments.
PI and the RRH-PI prodrugs were tested for cellular
uptake on several cell lines, including B16 (murine mela-
noma), Hepa 1-6 (mouse hepatoma), SKOV-3 (human
ovarian carcinoma), OVCAR-3 (human ovarian carci-
noma), Jurkat (human T-lymphocyte), 293 (human embry-
onic kidney), and MC38 (mouse colon carcinoma) cells.
Figures 3B and 3C show representative results after the
application of PI and II to Hepa 1-6 cells. Unmodified PI
stained very few cells (Figure 3B), while II yielded strong
nuclear staining in all of the cells (Figure 3C). With longer
camera exposure times, fluorescent signal could also be
detected within the membrane and cytoplasm of the cells
exposed to II (cytoplasmic PI is not as fluorescent as the
nuclear, DNA-intercalated PI), but not in cells exposed to
PI. Microscopic examination indicated that the cells that
took up II appeared to be morphologically intact. Similar
results were observed after the treatment of SKOV-3 cells
(Figures 3D and 3E). II that was hydrolyzed by premixing
with ITG (5 min) before application to the cells again
resulted in very few PI-positive cells (identical to treatment
with PI, data not shown), indicating that both prodrug
hydrolysis and the liberated hydrophobic moiety did not1068 Chemistry & Biology 14, 1065–1077, September 2007 ª200contribute to PI uptake. The RRH prodrug III was similarly
investigated for cellular uptake, and, in all cases, the
results paralleled those obtained with II (data not shown).
Additionally, results from the application of PI, II, and III on
other cell lines (OVCAR-3, Jurkat, 293, and MC38) were
similar to those detailed for the Hepa and SKOV-3 cell
lines, indicating that internalization of the RRH-PI was
not cell type specific.
Flow cytometry was used to quantitate prodrug delivery
to Jurkat cells. Flow cytometry of cell suspensions that
were treated with PI in aqueous solution (no OS, no mixing
chamber) indicated very low PI uptake in most cells, with
very few displaying a signal above 100 (0.3% ± 0.1%, con-
trol runs 1–4, Figure 3H). For cells that were suspended in
ITG, and passed through the mixing chamber with unmod-
ified PI (in DMSO), few PI-positive cells were observed
(8.4% ± 0.6%, PI runs 1–4). However, when the same
experiment was conducted with II in DMSO, flow cytome-
try indicated that nearly all cells were PI positive (99.5% ±
0.1%, II runs 1–4). These results were supportive of the
large influence that hydrophobization had on PI internali-
zation and correlated well with our observations by fluo-
rescent microscopy.
The stable derivative IV was also tested for cellular
uptake in SKOV-3 cells (Figures 3F and 3G). Immediately
after application of IV to cells, a diffuse signal was
observed along the cell membrane in the fluorescein
channel (Figure 3F). No fluorescent signal was observed
within the cytoplasm of the cell, even with longer camera
exposure times. After a 1 hr incubation, a more defined
punctate signal was observed (Figure 3G), likely due to
endocytosis of the membrane-bound derivative. This indi-
cated that hydrophobicity aided in membrane associa-
tion, but that, in the absence of lability, the hydrophobic
prodrug was sequestered and retained in the membrane.
In an attempt to clarify the cellular internalization of
RRH-PI, several experiments were conducted. One possi-
bility was that the prodrug induced membrane damage or
acute toxicity, leading to drug internalization by diffusion,
due to its amphipathicity. Hepa 1-6 cells were treated with
II and then with Calcein AM (live cell marker). Approxi-
mately 86% of the cells were both PI and calcein positive,
indicating viable cells (Figure 3I). Alternatively, Hepa 1-6
cells were treated with II and then with SYTOX Green
(dead cell marker), resulting in less than 5% of cells being
both PI and SYTOX Green positive (data not shown).
When PI was added to SKOV-3 cells at the same time
as IV or V, PI uptake by the cells was comparable to7 Elsevier Ltd All rights reserved
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Labile Hydrophobization for First-Pass Deliverycontrols (no IV or V). Lastly, a trypan blue assay for
membrane disruption indicated that neither V nor methyl
aniline silylated with chloro(dimethyl)octadecyl-silane
caused generalized membrane disruption (data not
shown). Based on these results, the hydrophobic agents
do not appear to assist in the cellular entry of another
molecule, suggesting that internalization is not due to
generalized membrane damage.
Structurally, we thought that micelles could be gener-
ated upon mixing of the prodrug with the aqueous solu-
tion. Analysis of IV (after mixing with ITG) by dynamic light
scattering indicated the formation of 36 nm particles
(range = 28–42 nm, 18.3 Mcps). Similarly, dynamic light
scattering analysis of V (after mixing with ITG) indicated
the formation of 36 nm particles (range = 36–66 nm, 2.1
Mcps). Instability in aqueous solution and absorption of la-
ser light (l 533 nm) prevented direct measurement of
RRH-PI prodrugs II and III by dynamic light scattering.
Samples were therefore analyzed qualitatively for the
presence of particles by measuring the 90 light scatter-
ing. Examination of IV (positive control) indicated a 15-
fold increase in signal intensity relative to ITG or PI in
ITG. However, the analysis of II and III by 90 light scatter-
ing indicated a maximum 2-fold increase in signal intensity
relative to PI. Based on these results, we cannot defini-
tively establish the presence of RRH-PI prodrug micelles.
Given that the stable derivative IV and the melphalan
derivative V did indicate the presence of micelles, it is
probable that micelles, although transient in nature due to
the rapid lability of the prodrug, do form for the RRH-
PI prodrugs.
In Vitro Cytotoxicity
In order to investigate the effects of labile hydrophobiza-
tion with C12PMMA on cytotoxicity, we tested melphalan
and the prodrug V on Hepa 1-6, MC38, and SKOV-3 cells
under conditions designed to mimic first-pass exposure.
Cells were exposed to varying concentrations of V in
DMSO for 4 min, and the cultures were assayed for viabil-
ity (WST-1, Dojindo Molecular Technologies) after 48 hr. In
Hepa 1-6 cells, the viability assay indicated an IC50 of 330
mM (±93 mM) (Table 2). Treatment with melphalan had
a slight effect, with 81% (±2.3%) cell viability at the highest
concentration tested (1458 mM). Previous studies have in-
dicated that lower concentrations of melphalan caused
higher cellular toxicity, but our experiments used shorter
times for drug exposure (4 min versus 48 hr) in order to
model first-pass exposure [47]. No toxicity was observed
from the DMSO/ITG vehicle alone. V that was premixed
with ITG containing 20 mM HEPES buffer (pH 6.5)
(10 min) to hydrolyze the prodrug before application to
the cells resulted in cell viability levels similar to those
observed with melphalan. Similar toxicity profiles were
observed in SKOV-3 and MC38 cells (Table 2).
Cell proliferation/toxicity studies were also conducted
by using RRH-PI compounds (Table 2). In Hepa 1-6 cells,
the viability assay at 24 hr posttreatment indicated an IC50
of 282 mM (±62 mM) for II (Table 2). PI had little effect, with
100% (±3.0%) cell viability at the highest concentrationChemistry & Biology 14, 1065–1077tested (1.25 mM). At 48 hr posttreatment, the viability as-
say indicated an IC50 of 334 mM (±72 mM) for II, while PI
again had little effect at the highest concentration tested
(93% ± 5.7% cell viability at 1.7 mM). II that was premixed
with ITG (10 min) before application to cells resulted in
levels of cell viability that were similar to those of the
PI-treated cells (108% ± 1.3% at 833 mM). The stable PI
derivative IV was also tested for toxicity in Hepa 1-6 cells
at 24 and 48 hr posttreatment, resulting in IC50s of 585
(±279 mM) and 429 mM (±37 mM), respectively. The toxicity
resulting from IV may have been the result of endocytosis
of the prodrug (hydrolysis of the amide would then yield
PI), or its cationic amphipathic property. Similar results
were obtained with SKOV-3 cells (Table 2).
In Vivo Delivery of RRH-PI Prodrugs
Encouraged by results from both the cellular uptake and
cytotoxicity studies, a tumor model was established in
mice with MC38 cells. Pathological evaluation was per-
formed on select animals from each experimental group
prior to testing to ensure arterialization of hepatic tumors
and minimal signs of necrosis/apoptosis. After 2–3 weeks
of tumor development, PI and RRH-PI were delivered via
a liver arterial bolus injection (LABI). Due to the small diam-
eter of the hepatic artery and its contraction after injection
(leading to thrombosis), solutions were delivered to the
right gastroduodenal artery for retrograde delivery to the
hepatic artery. After 5 min, the livers were harvested, sec-
tioned, and analyzed by fluorescent and confocal micros-
copy. Injection of II (0.150 mmol in 20 ml DMSO/200 ml ITG)
resulted in strong PI-positive nuclear staining of MC38
liver metastases, but very little PI staining in normal liver
parenchyma (Figures 4A and 4B). Hepatic arteries and
some cells in the portal triads were also PI positive
(Figure 4A, arrowhead), as were a few cells at the paren-
chyma-metastasis interface. No PI-positive cells were ob-
served in any other organ examined (heart, lung, spleen,
and kidneys) in any of the animals treated with II, indicat-
ing that II was hydrolyzed back to PI prior to encountering
other tissues. LABI with III resulted in a similar cellular up-
take pattern to that observed with II (data not shown).
LABI with PI or II that was premixed with ITG (10 min)
resulted in a relatively few PI-positive cells within the
MC38 metastases, presumably necrotic or apoptotic cells
(Figure 4C). Samples examined by confocal microscopy
indicated a similar signal pattern (Figures 4G–4J).
Confocal imaging was also utilized to approximate the
numbers of PI-positive cells after LABI in three different
regions of the liver: Region 1, MC38 metastases; Region 2,
portal triad areas; and Region 3, parenchyma representing
zone 2 of the hepatic unit. LABI with II resulted in an aver-
age of 94% of the cells in Region 1 being PI positive. In Re-
gion 2, an average of 23% of the cells were PI positive.
Positive cells in this region were comprised of arterial
cells, some adjoining hepatocytes, and bile duct cells (all
of which are exposed to II during the injection). In Region
3, an average of 1% of the cells were PI positive. These
data were used to estimate the overall percentage of non-
tumor cells in the liver that were PI positive. As Region 2, September 2007 ª2007 Elsevier Ltd All rights reserved 1069
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Labile Hydrophobization for First-Pass DeliveryFigure 3. Delivery of PI, II, and IV to Various Cell Cultures
(A) The aqueous solution and the RRH prodrug in OS are delivered to the chamber by independent syringe pumps, with passive mixing from
colliding flows.
(B–E) (B and D) PI or (C and E) II, 20 ml of 7.48 mM solution in DMSO, was mixed with ITG (200 ml) and added to the (B and C) Hepa 1-6 cells (mag-
nification = 3203) or (D and E) SKOV-3 cells (magnification = 1003). After 30 s, the drug solution was removed, and 2 ml growth media was again
added to the cells. The cells were immediately imaged with an Axiovert S100 fluorescent microscope (Zeiss), and the same fields were imaged
with phase-contrast illumination and in the rhodamine fluorescence channel.
(F and G) SKOV-3 cells were treated with IV (20 ml 7.48 mM solution in DMSO) and (F) immediately imaged on an Axioplan-2 fluorescent microscope
(Zeiss), or (G) incubated for 1 hr prior to imaging. The same fields were imaged with phase-contrast illumination and in the fluorescein fluorescence
channels, magnification = 3203.1070 Chemistry & Biology 14, 1065–1077, September 2007 ª2007 Elsevier Ltd All rights reserved
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Labile Hydrophobization for First-Pass Deliverycomprises less than 5%–7% of the liver (in humans, sim-
ilar in rodent) [48], the total number of PI-positive non-
tumor cells in the liver can be estimated to be 2%–3%.
In order to evaluate tumor cell and hepatocyte uptake
based on differences in vascular supply, RRH-PI prodrug
was delivered into the portal vein of normal and tumor-
bearing mice. No clamping of liver outflow was performed
in order to avoid pressure-induced delivery [49]. Intrapor-
tal injection of II to tumor-bearing mice with preserved
portal blood flow resulted in no signal within the metasta-
ses, and few hepatic and single nucleated blood cells be-
ing positive for PI (Figure 4D), likely due to RRH-PI being
sequestered by blood constituents [50]. When intraportal
delivery was performed with the portal vein and celiac
artery transiently clamped to occlude blood flow, there
was prominent labeling of portal structures and adjacent
cells, including hepatocytes (Figure 4E), but not of the
metastases. As with arterial injections, injection of unmod-
ified PI into the portal vein (with occluded blood flow)
resulted in a few labeled cells, either within the portal
structure or hepatocytes (Figure 4F).
Analyses of cell suspensions prepared from normal liver
samples after portal vein injections (occluded blood flow)
of II resulted in70% of the hepatocytes being PI positive.
Corresponding injections of PI resulted in1% of the cells
being PI positive. Nucleic acid (DNA and RNA) isolated
from the cell suspensions was analyzed by fluorescent
spectroscopy, indicating that 1.2% of the injected PI
was bound, as compared to 14% for II. This analysis
accounts for PI that was bound to the nucleic acid in the
hepatocytes, and not to PI that was still associated with
the membrane or unbound within the cell, which would
have been lost during nucleic acid isolation.
In addition to the MC38 model, we also performed pre-
liminary testing of RRH-PI delivery in other relevant synge-
neic murine liver metastases models, including Hepa 1-6
(hepatoma), B16 (melanoma), and NXS2 (neuroblastoma)
utilizing LABI. Similar levels of PI-positive cells were ob-
served; preferential staining of hepatic metastases and
very minimal involvement of parenchymal cells was seen
(data not shown). Additionally, in all cases, the results
with III paralleled the results detailed with II (data not
shown). Taken together, these results supported our
idea that the RRH approach enabled selective and first-
pass delivery of a drug to a tumor in vivo.
In Vivo Antiproliferative Effect
PI and III were intraportally injected (occluded blood flow)
into normal mice immediately after a 70% hepatectomy in
order to evaluate their effect on rapidly proliferating tissue.
At 2 days after treatment with PI, an average of 7.0%
(±2.2%) of the hepatocytes were in metaphase. In con-
trast, after treatment with III, an average of 2.3%
(±2.9%) of the hepatocytes were in metaphase. Further
studies were therefore conducted to determine whetherChemistry & Biology 14, 1065–107III could have an antitumor effect on mice bearing MC38
liver metastases (Figure 5). In this study, hydrolyzed
C12PMMA-PI (by premixing with ITG) was injected by
LABI as a control. Animals that received III exhibited in-
creased survival (r = 0.02), compared to the animals that
received the hydrolyzed C12PMMA-PI (HyC12PMMA-PI,
Figure 5), although survival was limited to a few days.
DISCUSSION
The conceptual basis of RRH prodrugs involves the use of
labile hydrophobicity to aid in cell uptake in a first-pass
delivery setting. While there are a variety of drugs with
modifiable groups that could be delivered to cells in this
fashion, antitumor compounds are one class of drugs
that are suited to the RRH-based, first-pass approach.
In particular, given the unique vascular architecture of
the liver, with portal blood supplying most normal hepatic
tissue and hepatic arterial blood supplying tumors within
the liver, the locoregional delivery of RRH therapeutics is
uniquely suited to the treatment of primary and metastatic
liver neoplasms.
Using PI as a reporter molecule, RRH modification
enabled PI’s uptake into almost 100% of the cells in cul-
ture (Figure 3) and 94% of the target cancer cells
in vivo (Figure 4). In vitro, the internalization was not cell
type specific, with all cell types examined indicating high
levels of intracellular PI delivery. In vivo, the internalization
was dependent on first-pass contact with the RRH pro-
drug. RRH modification was able to convert PI, a mem-
brane-impermeable intercalator, into a cytotoxic agent
by enabling its rapid delivery into cells in vitro under
conditions that modeled first-pass therapy (Table 2). The
cytotoxicity of the anticancer drug melphalan was also
dramatically improved after a similar modification and
short-term exposure to cells (Table 2).
The exact nature of the RRH prodrug internalization into
the cell is not fully understood at this time. In testing with
the stable derivative IV, only membrane-associated pro-
drug was immediately observed after addition to cells
(Figure 3F). In cells incubated for 1 hr after delivery of IV,
punctate staining was observed within the cytoplasm,
indicating endocytosis (Figure 3G). Membrane-associated
PI was similarly detected immediately after cellular expo-
sure to RRH-PI, by using long camera exposure times.
However, in the case of RRH-PI delivery, nuclear PI stain-
ing was observed immediately after RRH-PI delivery
(within 2 min, Figure 3). Nuclear staining indicates that
(a) RRH-PI rapidly inserted into the cell membrane, and
that (b) rapid hydrolysis of the hydrophobic modification
enabled diffusion of PI to the nucleus. Without the hydro-
lytic linkage, IV remained bound to the cell membranes.
In addition, RRH-PI was quickly observed in nuclei in cells
kept at 4C, indicating that the delivery did not require an
endocytic step [51] (data not shown). Additional testing(H) Flow cytometry was conducted on Jurkat cells after treatment with PI (control runs 1–4) and on a suspension of Jurkat cells in ITG, treated with PI
(PI runs 1–4) or II (II runs 1–4) through the mixing chamber. The results represent a histogram of the relative PI intensity of all single-cell events. (I)
Treatment of Hepa 1-6 cells with II then Calcein AM to determine live cells (magnification = 2003).7, September 2007 ª2007 Elsevier Ltd All rights reserved 1071
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Labile Hydrophobization for First-Pass DeliveryFigure 4. LABI and Portal Vein Delivery of PI and II to C57BL Mice
(A–J) After 3 weeks of MC38 tumor development, PI or II (0.150 mmol in 20 ml DMSO, 200 ml ITG) was delivered by LABI or portal vein injections. After 5
min, the livers were harvested, sectioned, and analyzed by fluorescent microscopy (Axioplan-2 fluorescent microscope with FITC emission filter,
Zeiss) or stained (green, actin; blue, nuclei) and analyzed by confocal microscopy (Laser LSM 510 confocal microscope, Zeiss). (A) LABI of II (mag-
nification = 1003, the arrowhead indicates the hepatic artery and surrounding cells). (B) LABI of II (magnification = 2003). (C) LABI of PI (magnification
= 2003, the arrowhead indicates the metastases boundary). (D) Portal vein injection with normal blood flow of II to a tumor-bearing mouse (magni-
fication = 2003, the arrow indicates the hepatic vein). (E and F) Portal vein injection of (E) II to a tumor-bearing mouse or (F) PI to a non-tumor-bearing
mouse with the portal vein and celiac artery clamped to occlude blood flow. The blood in the liver was flushed out with 1 ml ITG delivered through the1072 Chemistry & Biology 14, 1065–1077, September 2007 ª2007 Elsevier Ltd All rights reserved
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Labile Hydrophobization for First-Pass DeliveryTable 2. Mean IC50 Values for Drug/Prodrug in Various Cell Cultures by Using theWST Assay 24 and 48 hr after Drug
Exposure
Cell Type
Melphalan V PI II IV
48 hr 48 hr 24 hr 48 hr 24 hr 48 hr 24 hr 48 hr
Hepa 1-6 >1458a 330 (93) >1,250b >1,700b 282 (62) 334 (72) 585 (279) 429 (37)
SKOV-3 >1458c 384 (97) >1,250b >1,700b 194 (143) 257 (54) 455 (126) 342 (27)
MC38 1176 (150) 304 (94)
Cell viability was >90% in cultures exposed to the vehicle alone (DMSO/ITG). IC50 values are given as mM, SD.
a Cell viability was 80% of negative control (no treatment) at these maximum concentrations.
b Cell viability was >90% of negative control (no treatment) at these maximum concentrations.
c Cell viability was 70% of negative control (no treatment) at these maximum concentrations.indicated that the internalization was not a result of the
DMSO in the procedure [52, 53], nor was it due to general-
ized membrane damage, and that the cells were viable af-
ter treatment.
It is possible that the RRH-PI contacts the cell initially as
a micelle, followed by membrane binding similar to deter-
gent insertion into a membrane. The membrane-bound
RRH-PI then could enter the cell via a flip mechanism so
that PI is internal prior to its hydrolysis [54]. Doxorubicin
has been shown to internalize into cells by a flip mecha-
nism with a half-life of minutes [50]. In the case of phos-
pholipids, the rate of flip is generally on the order of hours,
although this rate can be more rapid in the presence of
polyunsaturated phospholipids and detergents [55].
Therefore, drug internalization due to a flip could be aided
by the detergent properties of the prodrug, resulting in
a very localized and transient membrane perturbation.
For membrane-bound prodrug hydrolyzed prior to inter-
nalization, our results suggest that this portion of drug
would be lost to the cell given that we were not able to
observe a hydrophobic derivative aid in the internalization
of another molecule.
A critical test for the RRH prodrug concept involved the
ability to demonstrate first-pass delivery to cells in vivo. In
a MC38 mouse liver tumor model, LABI with RRH-PI pro-
drugs resulted in widespread PI staining of the liver tumor
cells, while normal liver parenchyma had sparse PI stain-
ing (Figure 4). The non-tumor liver cells that were stained
were mainly cells of the hepatic artery. Quantitation with
confocal microscopy indicated that an average of 94%
of the cells in the MC38 metastases were PI positive, while
only 2%–3% of the non-tumor cells were PI positive
(Figure 4G). No PI-positive cells were observed in other or-
gans, indicating that the RRH-PI had hydrolyzed back to
PI prior to contact with other tissues. LABI with PI alone
resulted in relatively little PI uptake in tumors and normal
liver parenchyma.
Alternatively, when II was delivered to the liver via the
portal vein with the blood flow temporarily occluded (noChemistry & Biology 14, 1065–107clamping on liver outflow), a high percentage of hepato-
cytes were PI positive (Figure 4E), while the MC38 metas-
tases were relatively PI negative. Intraportal injection of II
into normal mice resulted in 70% of the hepatocytes
being positive for PI, with 14% of the administered
dose remaining in the liver (compared to 1% of the dose
when PI was injected). Although a majority of the PI is still
cleared, our results show a dramatic increase in cell
uptake.
We therefore tested the efficacy of the RRH-PI prodrug
III for antitumor response in a mouse MC38 liver metasta-
ses model. Survival was significantly (r = 0.02) prolonged
in the III-treated group compared to the control group
(Figure 5), although it was limited to a few days. Improved
survival may be possible by using higher dosing or repeat
delivery, as is done with TAC therapy. In the current study,
a single injection was employed due to surgical limitations.
Although the arterial system was undoubtedly targeted by
the RRH prodrug, as evidenced by the fluorescent micros-
copy studies, no detectable damage was observed; there-
fore, arterial targeting is unlikely to preclude repeat injec-
tions. These results therefore provide proof-of-principle
for the use of RRH to enable antitumor effects. Repeat in-
jections, although challenging in a mouse model, would be
possible in larger animals, likely leading to ameliorated
effects.
SIGNIFICANCE
This report introduces and demonstrates the use of
prodrugs with rapidly reversible hydrophobization for
improved cellular delivery of the drugs in vitro and
in vivo. In this study, designed to serve as a proof-of-
concept study, modification of the DNA intercalator
PI was conducted. Besides the aforementioned fluo-
rescent properties of PI that were critical to this study,
we believed that the electron-withdrawing effect of
the phenanthridinium on the exocyclic amines would
serve to dramatically destabilize the hydrophobicportal vein immediately prior to delivery of II or PI. Arrows indicate the portal vein; arrowheads indicate the hepatic vein (magnification = 4003). (G)
LABI delivery of II (magnification = 4003, the arrow indicates a metastatic artery in the rhodamine channel, the arrow indicates the portal tract in the
combined view, and the arrowheads indicate the metastasis boundary in the combined view, magnification = 4003). (H) Image from the center of
the metastasis from (G) (magnification = 6303). (I) Hepatic artery after LABI delivery of II to a non-tumor-bearing mouse (magnification = 6303).
(J) Hepatic artery after LABI delivery of PI to a non-tumor-bearing mouse (magnification = 6303).7, September 2007 ª2007 Elsevier Ltd All rights reserved 1073
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Labile Hydrophobization for First-Pass Deliveryderivatives toward hydrolysis. This was realized, as
RRH-PI prodrugs possess half-lives on the order of
10–20 s. Labile hydrophobization induced cellular in-
ternalization of PI by a rapid, non-endocytosis-driven
mechanism. Remote tissues were protected from the
highly active prodrugs due to the rapid lability of the
hydrophobic moiety.
In general terms, depending on the functional group
modified, and the type of attachment linkage used, it
should be possible to regulate the hydrolysis rate of
the prodrug, and therefore the active lifetime of the
prodrug for a desired treatment application. Although
this idea poses a very significant synthetic challenge,
our results with the delivery of PI have demonstrated
that this methodology allows for the development
of active therapeutics from cell-impermeable com-
pounds, potentially leading to therapeutics possess-
ing low systemic toxicity. Although the hydrolytic in-
stability of the RRH-PI prodrugs necessitated the
use of DMSO in the injection solution, alternative
mechanisms for lability could potentially be devel-
oped, such as rapid change in pH, thereby avoiding
the use of DMSO. Overall, this approach is particularly
applicable to first-pass treatment strategies, most no-
tably those involving liver tumors or ovarian cancer.
However, any tumor or organ that has an identifiable
vascular source could potentially be targeted, and it
therefore provides an exciting avenue to improve
chemotherapeutics for a variety of cancers and other
disorders.
EXPERIMENTAL PROCEDURES
All chemical reactions were carried out in a nitrogen or argon atmo-
sphere by using flame-dried glassware. Anhydrous N,N-dimethylfor-
mamide (DMF, Aldrich) and anhydrous dimethyl sulfoxide (DMSO,
Aldrich) were used without further purification. Potassium carbonate
(Aldrich) and molecular sieves (3 A˚, Aldrich) were flame dried under
Figure 5. Days of Survival after LABI Delivery of C12PMMA-PI
or Hydrolyzed C12PMMA-PI to C57BL Mice
After 3 weeks of MC38 tumor development, C12PMMA-PI or hydro-
lyzed C12PMMA-PI (0.150 mmol in 20 ml DMSO, 200 ml ITG) was
delivered by LABI. The mouse abdomen was closed 4 min after drug
treatment, and the animals were monitored for survival time.1074 Chemistry & Biology 14, 1065–1077, September 2007 ª20vacuum prior to use. Propidium iodide (PI, 95%, Aldrich) was used
without further purification. 1H-NMR spectroscopy was performed
on a Bruker AC+ 250, a Bruker AC+ 300, or a Varian Unity INOVA
400 spectrometer. Mass analysis was conducted on a PE Sciex API
150EX mass spectrometer. Cells were purchased from ATCC (Mana-
ssas, VA), unless otherwise noted, and cultured according to the
distributor’s instructions. Complete details on prodrug hydrolysis
and particle sizing can be found in the Supplemental Data available
with this article online.
Compound Preparation and Lability
N-Dodecyl-3-(4-methyl-2,5-dioxo-2,5-dihydro-furan-3-yl)-
propionamide, C12PMMA
To a solution of 3-(4-methyl-2,5-dioxo-2,5-dihydro-furan-3-yl)-pro-
pionic acid [41] (800 mg, 4.34 mmol) in dichloromethane (22 ml) was
added oxalyl chloride (0.41 ml, 4.56 mmol, Aldrich) dropwise under
nitrogen. The resulting solution was stirred at ambient temperature
for 6 hr and concentrated under reduced pressure. The resulting oil
was suspended in dichloromethane (22 ml), and dodecyl amine
(1.10 ml, 4.78 mmol, Aldrich), followed by diisopropylethylamine
(0.83 ml, 4.78 mmol, Aldrich), was added. After 4 hr, the solution was
concentrated under reduced pressure. The resulting reside was taken
up in EtOAc (150 ml), washed twice with HCl (20 ml, 1 N), washed once
with H20, dried (Na2SO4), filtered, and concentrated to afford a white
solid. The solid was purified by flash chromatography on silica
gel (40 3 160 mm, EtOAc/Hexanes 1:1 eluent) to afford 1.04 g
C12PMMA (68%) as a white solid. 400 MHz 1H-NMR (CDCl3, 99.8%,
ppm) d 5.720 (1H, s) 3.20 (2H, dt, J = 6.4, 7.0) 2.79 (2H, t, J = 7.0)
2.530 (2H, t, J = 7.0) 2.13 (3H, s) 1.55–1.42 (2H, m) 1.34–1.24 (18H,
m) 0.88 (3H, t, J = 7.0). 13C-NMR (CDCl3, 99.8%, ppm) d170.509,
166.194, 166.156, 143.007, 142.465, 39.974, 33.093, 32.116, 29.832,
29.786, 29.756, 29.733, 29.549, 29.481, 27.106, 22.890, 20.645,
14.321, 9.876. Molecular ion + 1 calculated for C20H33NO4 = 352.2,
found m/e = 352.2.
Synthesis of 3,8-Bis([(dimethyl)octadecylsilazyl] Amine)
5-(3,3-Diethyl-3-methylammonium Propyl) 6-Phenyl
Phenanthridinium Diiodide, II
To PI, chloro(dimethyl)octadecylsilane (6 eq., 95%, Aldrich), K2CO3 (10
eq.), and molecular sieves (3 A˚, 10 wt eq.) was added anhydrous DMF
or DMSO (7.5–15 mmol/ml final concentration). The resulting suspen-
sion was heated at 60C for 12 hr, cooled to ambient temperature,
centrifuged, filtered (0.2 mm Nylon membrane) under inert atmosphere,
and precipitated in diethyl ether to afford II as a purple solid. 300 MHz
NMR (N,N-dimethylformamide-d7, 99.5%, ppm) d 8.72 (2H, dd, J =
9.2, 6.6) 8.38 (1H, d, J = 1.7) 7.93–7.80 (5H, m) 7.74 (1H, dd, J = 9.1,
2.3) 7.48 (1H, dd, J = 9.1, 1.7) 6.66 (1H, s) 6.46 (1H, d, J = 2.3) 6.13
(1H, s) 4.59 (2H, m) 4.66–4.55 (2H, m) 3.88–3.75 (2H, m) 3.58–3.40
(2H, q, J = 7.2) 3.21 (3H, s) 2.62–2.45 (2H, m) 1.40–1.18 (70H, m)
0.90–0.84 (6H, m) 0.55–0.49 (4H, m) 0.3 (12H, s). In DMSO, lex max =
460 nm, lem max = 638 nm.
In some preparations, 1H-NMR analysis indicated the formation two
additional compounds as minor components in the reaction mixture
(<10%). A trisilylated PI was observed (based on integration), arising
from two silylation reactions taking place on one of the PI amino
groups. The second minor component was identified as the phenan-
thridinium salt of II (verified by independent synthesis, from the reac-
tion of PI and chloro(dimethyl)octadecylsilane in dichloromethane in
the absence of a base).
Synthesis of 3,8-Bis-(2-[2 Carboxyethylidene]-4-
[dodecarbamoyl]-1-oxo-butylamine) 5-(3,3-Diethyl-3-
methylammonium Propyl) 6-Phenyl Phenanthridinium
Diiodide, III
To PI, C12PMMA (3 eq.), K2CO3 (10 eq.), and molecular sieves (3 A˚,
10 wt eq.) was added anhydrous DMF or DMSO (7.5–15 mmol/ml final
concentration). The resulting suspension was heated at 60C for 12 hr,
cooled to ambient temperature, centrifuged, filtered (0.2 mm Nylon
membrane) under inert atmosphere, and precipitated in diethyl ether
to afford III as a mixture of isomers. Further attempts to purify III07 Elsevier Ltd All rights reserved
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300 MHz NMR (Dimethyl sulfoxide-d6, 99.5%, ppm) d 8.64 (2H, dd, J =
9.2, 8.2) 7.79–7.74 (5H, m) 7.56 (1H, dd, J = 9.2, 2.3) 7.41–7.29 (2H, m)
7.24–7.14 (1H, m) 6.67–6.62 (1 H, br m) 6.24 (1H, d, J = 2.3) 6.02–5.96
(2H, br) 4.43–4.33 (2H, br m) 3.45–2.70 (21H, m) 2.40–1.85 (8H, m)
1.52–0.98 (46H, m) 0.87–0.80 (6H, m). In DMSO, lex max = 460 nm,
lem max = 635 nm.
Synthesis of 3,8-Bis-undecylcarbanylamino 5-(3,3-Diethyl-3-
methylammonium Propyl) 6-Phenyl Phenanthridinium
Diiodide, IV
To PI (36.1 mg, 0.0540 mmol, Aldrich) in dichloromethane (10 ml) was
added lauroyl chloride (26.9 ml, 0.113 mmol, 2.1 eq., Aldrich), followed
by diisopropylethylamine (20.7 ml, 0.119 mmol, 2.2 eq., Aldrich). The
resulting solution was stirred at ambient temperature for 16 hr and
then partitioned in EtOAc/H20, washed twice with H20, washed once
with brine, dried (Na2SO4), filtered, and concentrated. The resulting
yellow solid was crystallized twice from acetonitrile to afford 53.7 mg
(96%) IV. Molecular ion calculated for C51H78N4O2I = 905.5, found
m/e = 905.7, molecular ion/2 calculated for C51H78N4O2 = 389.6, found
m/e = 389.9. 400 MHz 1H-NMR (Dimethyl sulfoxide-d6, 99.5%, ppm)
d 11.80 (1H, s) 10.74 (1H, s) 9.16 (1H, s) 9.11 (1H, d, J = 9.6) 9.06
(1H, d, J = 9.2) 8.62 (1H, d, J = 8.8) 8.48 (1H, dd, J = 9.2, 2.0) 8.02
(1H, d, J = 2.0) 7.85–7.74 (5H, m) 4.63–4.52 (2H, m) 3.33–3.25
(6H, m) 2.94 (3H, s) 2.42–2.28 (4H, m) 2.19–2.16 (2H, m) 1.68–1.45
(4H, m) 1.40–1.15 (38H, m) 0.85 (6H, t J = 5.8). In H2O, lex max = 443 nm,
lem max = 546 nm.
Synthesis of 3,9-Diaza, 2-(4-[bis(2-chloroethyl)amino] Phenyl
Methyl), 5-(2-Carboxyl Ethylidine), 4,8-Dioxo Uncosanoic
Acid, V
To melphalan (18.2 mg, 0.0596 mmol, Sigma), C12PMMA (41.9 mg,
0.119 mmol), K2CO3 (8.3 mg, 0.060 mmol), and molecular sieves
(3 A˚, 182 mg) was added anhydrous DMSO (1.82 ml). The resulting sus-
pension was heated at 60C for 12 hr, cooled to ambient temperature,
centrifuged, and filtered (0.2 mm membrane) under inert atmosphere,
to afford V as a mixture of isomers. Molecular ion + 1 calculated for
C33H51N3O6Cl2 = 656.3, found m/e = 655.5. Molecular ion  1 calcu-
lated for C33H51N3O6Cl2 = 654.3, found m/e = 636.3 (M-1-18). 400
MHz NMR (Dimethyl sulfoxide-d6, 99.5%, ppm) d 7.94–7.72 (2H, m)
6.90 (2H, d, JAB = 8.6) 6.57 (2H, d, JAB = 8.6) 4.16 (1H, m) 3.72–3.50
(8H, m) 3.323–3.181 (2H, m) 2.99–2.96 (2H, m) 2.48–2.44 (0.8H, m)
2.21 (1.2H, t, J = 7.4) 1.92 (1H, s) 1.81 (2H, s) 1.38–1.23 (20H, m)
0.85 (3H, t, J = 6.8).
In Vitro Cellular Uptake
Fluorescent microscopy studies were conducted with a three-laser
LSM 510 confocal microscope, an Axiovert S100 fluorescent micro-
scope, or an Axioplan-2 fluorescent microscope (all Zeiss) equipped
with filter sets for the rhodamine fluorescence channel (lex = BP
450/12, lem = LP 590 nm filter set) and the fluorescein fluorescent
channel (lex = BP 546/90, lem = LP 515 nm filter set). Imaging was
performed with an AxioCam digital camera (Zeiss), with AxioVision
imaging software (V 4.5, Zeiss). For all images, identical camera set-
tings and exposure times were used on comparative sample and con-
trol images. Images were processed with Photoshop (Adobe) for level
and brightness by using identical settings between sample and control
images.
Adherent cells were plated at 2.5 3 105 cells/well on 6-well plates
24 hr prior to testing. Details for the treatment of suspension cells,
including flow cytometry, can be found in the Supplemental Data.
The growth media were removed from individual wells, and the drug/
prodrug was immediately added to the well with the mixing chamber.
Detailed information for the construction and use of the mixing cham-
ber can be found in the Supplemental Data. Final drug/prodrug con-
centrations were 0.150 mmol in 220 ml total volume (20 ml OS, 200 ml
ITG). After 30 s, the drug solution was removed (aspirated), and 2 ml
complete media was added to the cells. Each condition was repeated
in two or three wells, and the cells were immediately examined by fluo-
rescent microscopy. Experiments conducted with prodrug that wasChemistry & Biology 14, 1065–107hydrolyzed prior to application to the cells followed a similar protocol;
however, the mixed solution was aged for 5 min prior to testing. Cell
viability experiments followed a similar protocol for drug treatment
(4 min). Calcein AM and SYTOX Green (both Invitrogen) were used
according to the manufacturer’s instructions.
For experiments conducted with IV, the cells were plated on 6-well
plates with coverslips. After treatment as described above, the cover-
slip was removed and inverted over one drop of media on a glass slide
for imaging. PI was also mixed with IV or V and then delivered to Hepa
1-6 and SKOV-3 cells. Mixing procedures can be found in the Supple-
mental Data.
Antiproliferative/Cytotoxic In Vitro Studies
In vitro cytotoxicity testing was conducted on Hepa 1-6 (mouse hepa-
toma), SKOV-3 (human ovarian carcinoma), and MC38 (mouse colon
carcinoma) cells by using a tetrazolium-based assay (WST-1, Dojindo
Molecular Technologies) [56]. For the WST assay, Hepa 1-6 (2.03 105
cells well), SKOV-3 (7.5 3 105 cells well), and MC38 (8.5 3 105 cells
well) cells were seeded in 1 ml media into 12-well plates 24 hr prior
to testing (starting confluency of 50%). After removal of media,
a drug/prodrug solution was added dropwise to quadruplicate wells,
by using the mixing chamber. Effective drug concentrations were cal-
culated from the amount of drug added in the total volume of OS and
aqueous solution. After 4 min of exposure, the drug solution was
removed, and 1 ml media was added to each well. After a 24–48 hr
incubation, WST-1 (20 ml 5 mM solution in PBS) and N-methylphenazo-
nium methyl sulfate (PMS, 20 ml 0.2 mM solution in PBS) were added,
and the cells were incubated for 1–4 hr. For MC38 cells, the amounts of
WST-1 and PMS were doubled. After incubation, 100 ml sample was
transferred to quadruplicate wells on a 96-well plate, and the absor-
bance (438 nm) values were measured on a SPECTRAmax Plus384 mi-
croplate spectrophotometer (Molecular Devices Corporation). Data
represent the mean A438 values of 16 wells, corrected for media con-
tribution and normalized against cells in media with no drug/prodrug
treatment (reported as percent cell viability ±SD). The concentration
of drug (mM) that is required for 50% inhibition in vitro is reported as
the IC50 (±SD) and was calculated from the best-fit line (Excel) for
a plot of effective drug concentration against percent cell viability.
In Vivo Studies
All animal experiments were performed in accordance with Institu-
tional Animal Care and Use Committee protocols. All surgical proce-
dures were performed under Isoflurane anesthesia and with a dissec-
tion microscope (MZ-6, Leica, Germany). A complete list of tumor
models and methods can be found in the Supplemental Data.
Drug/prodrug solutions (as described above) were delivered with the
mixing chamber via a liver arterial bolus injection (LABI) to the right
gastroduodenal artery (35 gauge needle) for retrograde delivery to
the hepatic artery, similar to procedures used clinically [57]. A com-
plete description of the experimental procedure can be found in Sup-
plemental Data. For confocal microscopy, the livers were harvested 5
min after LABI, snap frozen in O.C.T. compound, cryosectioned, and
stained (for confocal, green, actin [Alexa 488]; blue, nuclei [ToPro-3]).
Unstained sections of the same liver were examined by fluorescent mi-
croscopy with both rhodamine and long-pass FITC emission filters
(505 plus) in order to observe the low-magnification signaling pattern
(green signal is autofluorescence). For experiments designed to deter-
mine the number of PI-positive cells, five random fields of liver tumors
and five fields containing portal triad’s free of tumor were imaged. The
total number of cells and positive cells were counted to determine the
percentage of positive cells in the corresponding regions. For experi-
ments designed to monitor the antitumor effects of the prodrugs, III
(n = 11) or hydrolyzed III (n = 9) was injected as previously described,
the mouse abdomen was closed after drug treatment, and the animals
were monitored for survival time. Statistical analysis was conducted by
using a t test (two-tailed distribution and two sample, unequal vari-
ance, Excel).7, September 2007 ª2007 Elsevier Ltd All rights reserved 1075
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were clamped to occlude blood flow into the liver. In other experi-
ments, the portal vein and the celiac artery were not clamped, preserv-
ing full portal blood flow during the experiment. In all cases, the vena
cava was not clamped in order to avoid increased pressure within
the liver. For experiments with occluded blood flow, the blood in the
liver was flushed out with 1 ml ITG delivered through the portal vein
(1 min). Then, 0.300 mmol PI or II in 40 ml DMF was delivered together
with 400 ml ITG via the mixing chamber. Five minutes after injection, the
livers were perfused with 3 ml ITG to flush any drug remaining in the
vasculature, and livers were cryosectioned as described above, or
the hepatocytes were isolated [58]. Experimental details for nucleic
acid isolation and analysis from hepatocytes can be found in the Sup-
plemental Data.
The effect of drug/prodrug treatment was also evaluated on prolifer-
ating hepatocytes after a 70% partial hepatectomy on normal ICR
mice [59]. After the hepatectomy, drug/prodrug (0.150 mmol, 220 ml
total injection volume) was delivered to the liver via the portal vein by
using the mixing chamber. After 48 hr, the animals were sacrificed,
and the livers were harvested, formalin fixed, paraffin embedded, sec-
tioned, and H&E stained. A total of 50 random parenchymal fields per
animal were examined, and the number of hepatocyte mitotic figures
(metaphase) was determined together with the total number of hepa-
tocytes (2000 per animal). Results are reported as the percentage
of cells in metaphase (±SD).
Supplemental Data
Supplemental Data include Supplemental Experimental Procedures
used in this work and are available at http://www.chembiol.com/cgi/
content/full/14/9/1065/DC1/.
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